Universe Pharmaceuticals (NASDAQ:UPC) Trading 15.8% Higher – Should You Buy?

Universe Pharmaceuticals INC (NASDAQ:UPC)’s share price shot up 15.8% during trading on Thursday . The stock traded as high as $3.16 and last traded at $3.16. 9,287 shares were traded during trading, an increase of 80% from the average session volume of 5,156 shares. The stock had previously closed at $2.73.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Universe Pharmaceuticals in a report on Tuesday, February 3rd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Universe Pharmaceuticals has a consensus rating of “Sell”.

Universe Pharmaceuticals Trading Up 15.8%

The business has a 50-day simple moving average of $3.08 and a 200-day simple moving average of $3.93.

Universe Pharmaceuticals (NASDAQ:UPC) last released its quarterly earnings results on Thursday, January 29th. The company reported $0.69 EPS for the quarter. The firm had revenue of $8.92 billion during the quarter.

About Universe Pharmaceuticals

Universe Pharmaceuticals, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for ocular diseases. The company’s primary research efforts center on small-molecule compounds designed to address unmet needs in glaucoma, ocular hypertension and post-surgical ocular inflammation. By leveraging targeted enzyme inhibition and proprietary formulation technologies, Universe aims to bring forward topically administered medications that combine efficacy with an improved safety profile versus existing treatments.

The company’s lead candidate, UPC-1001, has been advanced into clinical trials for the treatment of open-angle glaucoma and ocular hypertension, where it seeks to lower intraocular pressure through a unique mechanism of action.